The Centrality of Obesity in the Course of Severe COVID-19
Open Access
- 11 March 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 12, 620566
Abstract
The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global public health challenge. Most patients do not experience severe complications, but approximately 25% of patients progress to acute respiratory distress syndrome (ARDS), and the mortality rate is approximately 5–7%. Clinical findings have determined several risk factors for severe complications and mortality in COVID-19 patients, such as advanced age, smoking, obesity, and chronic diseases. Obesity is a common and serious health problem worldwide that initiates a cascade of disorders, including hypertension, cardiovascular disease (CVD), diabetes mellitus, and chronic kidney disease (CKD). The presence of these disorders is linked to a more severe course of COVID-19. Given the “epidemic” of obesity worldwide and the importance of obesity in the progression of COVID-19, we investigated the mechanisms through which obesity increases the susceptibility to and severity of COVID-19 to support the selection of more appropriate therapies for individuals with obesity.Keywords
Funding Information
- National Key Research and Development Program of China (No. 2018YFC1312103 (LX))
- National Natural Science Foundation of China (No. 81972237 (LX), No. 81772623 (LX))
This publication has 114 references indexed in Scilit:
- Preferential apelin‐13 production by the proprotein convertase PCSK3 is implicated in obesityFEBS Open Bio, 2013
- The acute respiratory distress syndromeJournal of Clinical Investigation, 2012
- Meditation or Exercise for Preventing Acute Respiratory Infection: A Randomized Controlled TrialThe Annals of Family Medicine, 2012
- Blocking eIF4E-eIF4G Interaction as a Strategy To Impair Coronavirus ReplicationJournal of Virology, 2011
- Adipokines in inflammation and metabolic diseaseNature Reviews Immunology, 2011
- Visceral ObesityHypertension, 2009
- ACE2 is expressed in mouse adipocytes and regulated by a high-fat dietAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2008
- Increased Expression of Visfatin in Macrophages of Human Unstable Carotid and Coronary AtherosclerosisCirculation, 2007
- Adiponectin differentially regulates cytokines in porcine macrophagesBiochemical and Biophysical Research Communications, 2004
- Cloning of adiponectin receptors that mediate antidiabetic metabolic effectsNature, 2003